SHAREHOLDER ALERT: VLTA IBM AUPH: Vincent Wong Law Firms Remind Investors of Important Class Action Deadlines

0

The Law Firms of Vincent Wong announces that class action lawsuits have been filed on behalf of certain shareholders of the following companies. If you suffered a loss, you have until the lead plaintiff’s deadline to ask the court to name you as the lead plaintiff. There will be no obligation or cost to you

Volta Inc. (NYSE: VLTA)

If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/volta-inc-loss-submission-form?prid=26143&wire=1
Lead Applicant Deadline: May 31, 2022
Course period: August 2, 2021 – March 28, 2022

The allegations against VLTA include that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. (“Legacy Volta”) and Tortoise Acquisition Corp. II; (2) as a result, the Company had underestimated its net loss for the third quarter of 2021; (3) there were material weaknesses in the Company’s internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, the founders of Legacy Volta would soon leave the Company; (6) as a result, the Company’s financial results would be adversely affected; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked reasonable basis.

International Commercial Machinery Society (NYSE: IBM)

If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/international-business-machines-corporation-loss-submission-form?prid=26143&wire=1
Lead Applicant Deadline: June 6, 2022
Course period: April 4, 2017 – October 20, 2021

The allegations against IBM include the following: (i) Revenue and Growth of Strategic Imperatives, Revenue and Growth of CAMSS and Components of CAMSS, and Revenue and Growth of Company Segments have been artificially inflated by due to unwarranted reclassification of revenues from non-strategic to strategic make such revenues eligible for treatment as strategic imperatives revenues; (ii) the Company’s current success and positive future growth prospects regarding its strategic imperative business strategy have been fueled by the improper reclassification of revenues from non-strategic to strategic to make such revenues eligible for treatment as corporate income. Strategic Imperative and therefore (iii) the Company misled the market by portraying the financial performance and future prospects of the Company’s Strategic Imperative as more favorable than it actually was due to the improper reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)

If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?prid=26143&wire=1
Lead Applicant Deadline: June 14, 2022
Course period: May 7, 2021 – February 25, 2022

The allegations against the AUPH include that: (i) Aurinia was experiencing a decline in revenue; (ii) Aurinia’s 2022 sales outlook for the Company’s only product it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would be well below expectations; (iii) as a result, the Company had grossly overestimated LUPKYNIS’ business prospects; (iv) as a result, the Company had exaggerated its financial situation and/or its outlook for 2022; and (v) as a result, the Company’s public statements were materially false and misleading at all material times.

For more information, contact Vincent Wong, Esq. either by email [email protected] or by phone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Lawyer advertisement. Prior results do not guarantee similar results.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Office 304
New York, NY 10002
Such. 212.425.1140
Fax. 866.699.3880
Email: [email protected]

THE SOURCE: The law firms of Vincent Wong

See the source version on accesswire.com:
https://www.accesswire.com/698046/SHAREHOLDER-ALERT-VLTA-IBM-AUPH-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Share.

About Author

Comments are closed.